ALBUQUERQUE, N.M., July 16,
2024 /PRNewswire/ -- T-Neuro Pharma, a leading
biotechnology company dedicated to developing innovative
diagnostics and therapeutics for neurodegenerative diseases,
announced the publication of a landmark research article in
Proceedings of the National Academy of Sciences (PNAS), a
peer-reviewed journal of the National Academy of Sciences. The
article, "Antigen-Specific Age-Related Memory CD8 T Cells Induce
and Track Alzheimer's-Like Neurodegeneration," details a
significant breakthrough in understanding the early events and
progression of Alzheimer's disease.
Key Findings:
- Targeting Early Events in Alzheimer's: Unlike
traditional approaches that focus on the symptoms of Alzheimer's,
such as plaques and tangles, T-Neuro Pharma's research identifies
and targets earlier events in the disease's progression.
- Groundbreaking Discovery: The research team has
identified a critical event that likely occurs before the formation
of plaques and tangles, representing a significant advancement in
understanding the disease's early mechanisms.
- Role of T Cells in Alzheimer's: The study reveals that a
specific population of Tcells enters the brain and targets neurons,
initiating a cascade of events that lead to the hallmark
pathologies of Alzheimer's and cognitive decline.
- Early Detection in Humans: These T cells not only
accumulate in the brains of Alzheimer's patients, but can also be
detected disappearing from blood, enabling the identification of
patients early in the disease progression and offering the
potential for timely intervention.
- Future Therapeutic Implications: The findings not only
pave the way for early diagnosis, but also open up new avenues for
therapeutic development by targeting these T cells, potentially
altering the course of the disease and improving patient
outcomes.
"This study is the closest we've come to identifying a singular
factor acting before amyloid and tau — the proteins responsible for
brain plaques and tangles — in sporadic Alzheimer's disease," says
Christopher Wheeler, Ph.D., lead
author of the study and CSO of T-Neuro Pharma. "Since this depends
on a kind of immune cell that is easy to monitor and control, we
can use this to devise new ways to help diagnose and possibly treat
Alzheimer's earlier. More work needs to be done to determine if the
approaches inspired by our work can be applied to all patients with
non-inherited forms of Alzheimer's, but early evidence has been
very encouraging."
Kristina Trujillo, Ph.D., CEO of
T-Neuro Pharma, says the findings represent a significant step
forward in the early detection and intervention of Alzheimer's,
which is vital for improving the quality of life for patients and
their families.
"We are excited about the potential impact of this work to
ultimately improve a patient's quality of life and offer hope for a
future with more effective treatments," Trujillo says.
About T-Neuro Pharma
T-Neuro Pharma is a clinical-stage biopharmaceutical company
that develops diagnostics and disease-modifying therapies for
Alzheimer's and other neurodegenerative diseases. The company
targets the root cause of these devastating conditions, to improve
the lives of patients and their families. For more information,
please visit the https://tneuropharma.com or @Tneuropharma.com for
media interviews.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/t-neuro-pharma-announces-publication-of-groundbreaking-alzheimers-research-in-prestigious-journal-302197383.html
SOURCE T-Neuro Pharma